Literature DB >> 29157362

Detecting Visual Field Progression.

Ahmad A Aref1, Donald L Budenz2.   

Abstract

Timely detection of glaucomatous progression is crucial in the delivery of glaucoma care. Clinical judgment may be used to make this assessment, but relatively modest agreement among practitioners supports the use of complementary methods. Event-based analyses take into account expected localized test-retest variabilities in sensitivity, and trend-based analyses are helpful for determining and predicting overall visual function. Landmark clinical trials have used various visual field progression criteria as end points with variable performances. Short- and long-term fluctuations as well as inadequate testing frequency are limitations in visual field analysis for glaucomatous progression. Ongoing improvements in statistical techniques as well as incorporation of functional and structural measures into a single model likely will lead to an enhanced ability to detect glaucomatous progression and will allow for more timely and appropriate therapy.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29157362     DOI: 10.1016/j.ophtha.2017.05.010

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

Review 1.  Precision medicine to prevent glaucoma-related blindness.

Authors:  Sayoko E Moroi; David M Reed; David S Sanders; Ahmed Almazroa; Lawrence Kagemann; Neil Shah; Nakul Shekhawat; Julia E Richards
Journal:  Curr Opin Ophthalmol       Date:  2019-05       Impact factor: 3.761

2.  Agreement and Predictors of Discordance of 6 Visual Field Progression Algorithms.

Authors:  Osamah J Saeedi; Tobias Elze; Loris D'Acunto; Ramya Swamy; Vikram Hegde; Surabhi Gupta; Amin Venjara; Joby Tsai; Jonathan S Myers; Sarah R Wellik; Carlos Gustavo De Moraes; Louis R Pasquale; Lucy Q Shen; Michael V Boland
Journal:  Ophthalmology       Date:  2019-02-04       Impact factor: 12.079

3.  Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.

Authors:  Peter A Campochiaro; Mustafa Iftikhar; Gulnar Hafiz; Anam Akhlaq; Grace Tsai; Dagmar Wehling; Lili Lu; G Michael Wall; Mandeep S Singh; Xiangrong Kong
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Comparison of Methods to Detect and Measure Glaucomatous Visual Field Progression.

Authors:  Alessandro Rabiolo; Esteban Morales; Lilian Mohamed; Vicente Capistrano; Ji Hyun Kim; Abdelmonem Afifi; Fei Yu; Anne L Coleman; Kouros Nouri-Mahdavi; Joseph Caprioli
Journal:  Transl Vis Sci Technol       Date:  2019-09-11       Impact factor: 3.283

5.  Assessing Glaucoma Progression Using Machine Learning Trained on Longitudinal Visual Field and Clinical Data.

Authors:  Avyuk Dixit; Jithin Yohannan; Michael V Boland
Journal:  Ophthalmology       Date:  2020-12-25       Impact factor: 14.277

6.  Visual Subfield Progression in Glaucoma Subtypes.

Authors:  Wei-Wen Su; Shian-Sen Hsieh; Shih-Tsung Cheng; Cheng-Wen Su; Wei-Chi Wu; Henry Shen-Lih Chen
Journal:  J Ophthalmol       Date:  2018-03-21       Impact factor: 1.909

7.  An Artificial Intelligence Approach to Detect Visual Field Progression in Glaucoma Based on Spatial Pattern Analysis.

Authors:  Mengyu Wang; Lucy Q Shen; Louis R Pasquale; Paul Petrakos; Sydney Formica; Michael V Boland; Sarah R Wellik; Carlos Gustavo De Moraes; Jonathan S Myers; Osamah Saeedi; Hui Wang; Neda Baniasadi; Dian Li; Jorryt Tichelaar; Peter J Bex; Tobias Elze
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-01-02       Impact factor: 4.799

8.  Artificial Intelligence Algorithms to Diagnose Glaucoma and Detect Glaucoma Progression: Translation to Clinical Practice.

Authors:  Anna S Mursch-Edlmayr; Wai Siene Ng; Alberto Diniz-Filho; David C Sousa; Louis Arnold; Matthew B Schlenker; Karla Duenas-Angeles; Pearse A Keane; Jonathan G Crowston; Hari Jayaram
Journal:  Transl Vis Sci Technol       Date:  2020-10-15       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.